^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BCMA CAR-T cell therapy
i
Other names: BCMA CAR-T cell therapy, BCMA CAR-T cells, BCMA-Targeted prime CAR-T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chongqing Precision Biotech
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
1year
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=80, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jan 2023 --> Dec 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
IL6 (Interleukin 6)
|
BCMA CAR-T cell therapy
1year
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
IL6 (Interleukin 6)
|
BCMA CAR-T cell therapy
3years
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=80, Recruiting, Chongqing Precision Biotech Co., Ltd | Active, not recruiting --> Recruiting
Clinical • Enrollment open • CAR T-Cell Therapy
|
IL6 (Interleukin 6)
|
BCMA CAR-T cell therapy
Share via
